

May 27, 2014



Boston Therapeutics to Present at SeeThruEquity Microcap Investor Conference on May 28 and Marcum Microcap Conference on May 29

President Ken Tassey, Jr. to Discuss Recent Business Developments and Growth Strategy

MANCHESTER, NH -- (Marketwired) -- 05/27/14 -- [Boston Therapeutics, Inc.](#) (BTI) (OTCQB: BTHE), a leading developer of compounds that address diabetes using complex carbohydrate chemistry, today announced that President Kenneth A. Tassey, Jr. will present at two upcoming conferences. Mr. Tassey will provide an overview of the Company, recent business developments and growth strategy.

At the SeeThruEquity Third Annual Microcap Investor Conference on Wednesday, May 28 in New York City, Mr. Tassey will present at 11:30 am ET.

SeeThruEquity is an equity research and corporate access firm focused on companies with less than \$1 billion in market capitalization. For more information or to register, please visit <http://www.seethru-equity.com/#!upcomingconference/cc6n>.

At the Third Annual Marcum Microcap Conference to be held on Thursday, May 29 in New York City, Mr. Tassey will present in the Winter Garden Room at 1:30 pm ET.

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than \$500 million in market capitalization. For more information or to register, please visit the conference website at <http://www.marcumllp.com/microcap> or download the free official conference app for the iPhone, iPad, or for Android mobile devices in Apple's App Store and the Google Play Market.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320 (formerly PAZ320), a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also produces and sells SUGARDOWN[®], a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact:

Boston Therapeutics, Inc.
Anthony Squeglia
Chief Financial Officer
Phone: 603-935-9799
Email: anthony.squeglia@bostonti.com
www.bostonti.com

Source: Boston Therapeutics